+

EA200100899A1 - ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ) - Google Patents

ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ)

Info

Publication number
EA200100899A1
EA200100899A1 EA200100899A EA200100899A EA200100899A1 EA 200100899 A1 EA200100899 A1 EA 200100899A1 EA 200100899 A EA200100899 A EA 200100899A EA 200100899 A EA200100899 A EA 200100899A EA 200100899 A1 EA200100899 A1 EA 200100899A1
Authority
EA
Eurasian Patent Office
Prior art keywords
variants
identification
molecules
inhibitors
cpla2
Prior art date
Application number
EA200100899A
Other languages
English (en)
Inventor
Андре Десен
Джасбир С. Сеера
Уильям С. Сомерс
Марк Л. Стал
Original Assignee
Джинетикс Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джинетикс Инститьют, Инк. filed Critical Джинетикс Инститьют, Инк.
Publication of EA200100899A1 publication Critical patent/EA200100899A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

В данном изобретении представлена кристаллическая cPLA. С использованием данного материала была также установлена кристаллическая структура cPLA. Кроме того, предложены модели на основе данной кристаллической структуры. Описаны также способы идентификации ингибиторов активности и связывания мембраны cPLAс помощью данных моделей.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100899A 1999-02-15 2000-02-14 ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ) EA200100899A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/250,083 US6801860B1 (en) 1999-02-15 1999-02-15 Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
PCT/US2000/003745 WO2000047763A1 (en) 1999-02-15 2000-02-14 CRYSTAL STRUCTURE OF cPLA2, AND METHODS OF IDENTIFYING AGONISTS AND ANTAGONISTS USING SAME

Publications (1)

Publication Number Publication Date
EA200100899A1 true EA200100899A1 (ru) 2002-04-25

Family

ID=22946256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100899A EA200100899A1 (ru) 1999-02-15 2000-02-14 ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ)

Country Status (23)

Country Link
US (1) US6801860B1 (ru)
EP (1) EP1155144A4 (ru)
JP (1) JP2002540766A (ru)
KR (1) KR20010103010A (ru)
CN (1) CN1238520C (ru)
AU (1) AU779488B2 (ru)
BG (1) BG105886A (ru)
BR (1) BR0008231A (ru)
CA (1) CA2362612A1 (ru)
CZ (1) CZ20012933A3 (ru)
EA (1) EA200100899A1 (ru)
EE (1) EE200100426A (ru)
HK (1) HK1040745A1 (ru)
HR (1) HRP20010678A2 (ru)
HU (1) HUP0200554A3 (ru)
IL (1) IL144673A0 (ru)
MX (1) MXPA01008192A (ru)
NO (1) NO20013947L (ru)
NZ (1) NZ514176A (ru)
PL (1) PL351242A1 (ru)
SK (1) SK11782001A3 (ru)
TR (1) TR200102366T2 (ru)
WO (1) WO2000047763A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001286931A1 (en) 2000-08-30 2002-03-13 The Salk Institute For Biological Studies Methods and compositions for determining isomerase enzymatic activity
AU2001290240A1 (en) 2000-09-19 2002-04-02 Kyowa Hakko Kogyo Co. Ltd. Polypeptide having phospholipase a2 actiivty
WO2002038575A1 (en) * 2000-11-07 2002-05-16 I.R.B. Istituto Di Ricerche Biotecnologiche S.R.L. Glycerophosphoinositol derivatives as modulators of cytosolic a2 phospholipase
CA2439182C (en) * 2001-02-22 2009-04-14 Japan Science And Technology Corporation Novel calcium-independent phospholipases a2, genes thereof and promoter of the same
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8206753B2 (en) 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7666449B2 (en) * 2001-06-20 2010-02-23 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
CA2503196C (en) * 2002-10-21 2011-08-02 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
MXPA05012584A (es) * 2003-05-22 2006-05-25 Metaproteomics Llc Composiciones farmaceuticas anti-inflamatorias para disminuir la inflamacion, y tratamiento o prevencion de toxicidad gastrica.
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
KR20070086079A (ko) * 2004-11-13 2007-08-27 메타프로테오믹스, 엘엘씨 사이클로옥시게나제-2의 억제를 나타내는 조성물
WO2006088906A2 (en) 2005-02-15 2006-08-24 Dana-Farber Cancer Institute, Inc. Modulation of muc1 activity
US20080248131A1 (en) * 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
WO2007024940A2 (en) 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
AU2006321727A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and Acacia products
TW200819121A (en) * 2006-06-20 2008-05-01 Metaproteomics Llc Hexahydro-isoalpha acid based protein kinase modulation cancer treatment
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US8012695B2 (en) 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
JP2010522190A (ja) * 2007-03-19 2010-07-01 メタプロテオミクス， エルエルシー 骨及び関節の健康を助成するための方法と組成物
AU2008251756B2 (en) * 2007-05-11 2013-06-06 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
AU2008335156A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
CN102066303A (zh) * 2008-04-02 2011-05-18 麦特普罗泰欧米克斯有限公司 取代1，3-环戊二酮减弱的内皮炎症以及内皮-单核细胞相互作用
EP2352508B1 (en) 2008-10-17 2014-04-02 Dana-Farber Cancer Institute, Inc. Muc-1 cytoplasmic domain peptides as inhibitors of cancer
FI20105629A0 (fi) * 2010-06-03 2010-06-03 Estaja Oy Menetelmä lipidiaktivoituvien entsyymien peptidi-inhibiittoreiden valmistamiseksi ja menetelmällä valmistettuja peptidejä
CA3128999C (en) 2013-03-15 2023-09-12 GLAdiator Biosciences, Inc. Gla domains as targeting agents
MX2020002442A (es) 2017-09-05 2020-07-13 Gladiator Biosciences Inc Metodo de direccionamiento de exosomas.
CN117187211B (zh) * 2023-08-04 2025-04-01 华南理工大学 一种磷脂酶c晶体及磷脂酶c突变体的制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622832A (en) 1990-02-28 1997-04-22 Genetics Institute, Inc. Arachidonic acid releasing phospholipase A2 enzyme and methods of use
CA2061738A1 (en) * 1991-03-01 1992-09-02 Ruth M. Kramer Antibodies reactive with human cytosolic phospholipase a2
IL101507A0 (en) 1991-04-17 1992-12-30 Lilly Co Eli Compounds,vectors and methods for expressing human,cytosolic phospholipase a2
US5221410A (en) 1991-10-09 1993-06-22 Schering Corporation Crystal forming device
US5466595A (en) 1994-07-27 1995-11-14 Genetics Institute, Inc. Calcium independent cytosolic phospholipase A2/B enzymes
US6083711A (en) * 1996-05-15 2000-07-04 Smithkline Beecham Corporation Proteases compositions capable of binding to said site, and methods of use thereof

Also Published As

Publication number Publication date
CA2362612A1 (en) 2000-08-17
CN1238520C (zh) 2006-01-25
BG105886A (en) 2002-05-31
US6801860B1 (en) 2004-10-05
BR0008231A (pt) 2001-10-30
HUP0200554A3 (en) 2006-06-28
EP1155144A1 (en) 2001-11-21
EP1155144A4 (en) 2002-08-28
TR200102366T2 (tr) 2002-02-21
CZ20012933A3 (cs) 2002-02-13
EE200100426A (et) 2002-12-16
HK1040745A1 (zh) 2002-06-21
SK11782001A3 (sk) 2002-03-05
IL144673A0 (en) 2002-05-23
KR20010103010A (ko) 2001-11-17
WO2000047763A1 (en) 2000-08-17
HRP20010678A2 (en) 2003-08-31
AU2993700A (en) 2000-08-29
CN1348502A (zh) 2002-05-08
NO20013947D0 (no) 2001-08-14
MXPA01008192A (es) 2002-10-23
JP2002540766A (ja) 2002-12-03
AU779488B2 (en) 2005-01-27
NZ514176A (en) 2004-09-24
HUP0200554A2 (en) 2002-06-29
PL351242A1 (en) 2003-04-07
NO20013947L (no) 2001-10-10

Similar Documents

Publication Publication Date Title
EA200100899A1 (ru) ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ)
ATE338951T1 (de) Vorrichtung zur automatischen durchführung von laboratoriumprüfungen
DE69735445D1 (de) Abspaltbare, nicht-flüchtige moleküle zur massenmarkierung
DE60116322D1 (de) Vorrichtung zur aktiven kompensation von aberrationen in einem optischen system
BRPI0002963B8 (pt) processo e dispositivo medidor eletroquímico para medir uma concentração de analito em uma amostra.
DE69917372D1 (de) Vorrichtung zur Quantifizierung von Substraten
DE60026688D1 (de) Vorrichtung zur fokussierter probennahme von formations flüssigkeit.
BR0009206A (pt) Isolamento e análise de proteina
DK0943097T3 (da) Fremgangsmåde til at påvise IgE
ATE278803T1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
FR2847267B1 (fr) Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2
ATE335845T1 (de) Elektrophoretische analyse von molekülen mit immobilisierten sonden
WO2001042786A3 (en) System for cell based screening : cell spreading
DE69941688D1 (de) Immunoassays unter verwendung von sers (surface enhanced raman scattering)
DE69937835D1 (de) Antikörper für apoptosemarker und anwendungsverfahren
WO2002093129A3 (en) Methods for analyzing interactions between proteins in live and intact cells
DE60311973D1 (de) Substrat und verfahren zum messen elektrophysiologischer eigenschaften von zellmembranen
BR0311318A (pt) Inibidores de peptìdeo desformilase
DE59904458D1 (de) Vorrichtung zur dynamischen anregung von plattenlautsprechern
ATE333510T1 (de) Enzymatische messung von mycophenolsäure
ATE404692T1 (de) Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.
DE60038363D1 (de) Detektion von kleinen molekülen mit piezo-elektrischem sensor
DE60037595D1 (de) Vorrichtung zur zerstörungsfreien prüfung
WO2001042503A3 (en) Apparatus and methods for drug screening based on nucleic acid analysis
FI20031089L (fi) Kappaleiden tunnistusmenetelmä sekä järjestelmä merkin sisällön selvittämiseksi
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载